Approach to the treatment-experienced patient.
暂无分享,去创建一个
[1] J. Church. Potent Antiretroviral Effect of MK-0518, a Novel HIV-1 Integrase Inhibitor, in Patients With Triple-Class Resistant Virus , 2007, Pediatrics.
[2] Wei Huang,et al. Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen. , 2007, The Journal of infectious diseases.
[3] Eoin Coakley,et al. Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] Rebecca Hoh,et al. Rapid Emergence of Enfuvirtide Resistance in HIV-1-Infected Patients: Results of a Clonal Analysis , 2006, Journal of acquired immune deficiency syndromes.
[5] Michael S Saag,et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. , 2006, Topics in HIV medicine : a publication of the International AIDS Society, USA.
[6] P. Anderson,et al. Comment on: suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir. , 2006, The Journal of antimicrobial chemotherapy.
[7] V. Soriano,et al. Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir. , 2006, The Journal of antimicrobial chemotherapy.
[8] Laura Galli,et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study) , 2006, AIDS.
[9] Joel E Gallant,et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. , 2006, The New England journal of medicine.
[10] J. Chmiel,et al. Transient viremia in HIV-infected patients and use of plasma preparation tubes. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] Rebecca Hoh,et al. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. , 2005, The Journal of infectious diseases.
[12] D. Edwards,et al. HIV-1 Drug Resistance Evolution Among Patients on Potent Combination Antiretroviral Therapy With Detectable Viremia , 2005, Journal of acquired immune deficiency syndromes.
[13] B. Gazzard,et al. British HIV Association (BHIVA) guidelines for the treatment of HIV‐infected adults with antiretroviral therapy (2005) , 2005, HIV medicine.
[14] R. Haubrich,et al. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575 , 2005, AIDS.
[15] Tara L. Kieffer,et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. , 2005, JAMA.
[16] Steve A Castillo,et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[17] Tara L. Kieffer,et al. Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] Neil Parkin,et al. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. , 2004, The Journal of infectious diseases.
[19] R. Elston,et al. GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks , 2004, AIDS.
[20] Roland Tubiana,et al. Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097) , 2004, AIDS.
[21] R. Paredes,et al. Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study. , 2003, The Journal of infectious diseases.
[22] Gary Collins,et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. , 2003, The New England journal of medicine.
[23] J. Montaner,et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. , 2003, The New England journal of medicine.
[24] D. Havlir,et al. Virtual Inhibitory Quotient Predicts Response to Ritonavir Boosting of Indinavir-Based Therapy in Human Immunodeficiency Virus-Infected Patients with Ongoing Viremia , 2002, Antimicrobial Agents and Chemotherapy.
[25] Brian G Gazzard,et al. The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to < 400 copies/ml , 2002, AIDS.
[26] R. Schooley,et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study , 2002, AIDS.
[27] A. Sönnerborg,et al. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy , 2002, AIDS.
[28] Robert W. Shafer,et al. Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance , 2002, Clinical Microbiology Reviews.
[29] Pierre-Marie Girard,et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial , 2002, AIDS.
[30] Michael Ames,et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy , 2002, AIDS.
[31] A. Antinori,et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA) , 2002, AIDS.
[32] Lidia Ruiz,et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial , 2002, AIDS.
[33] M. Mouroux,et al. Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure. , 2001, AIDS.
[34] Steve Kaye,et al. Transient Relapses (“Blips”) of Plasma HIV RNA Levels During HAART Are Associated With Drug Resistance , 2001, Journal of acquired immune deficiency syndromes.
[35] V. Soriano,et al. Drug resistance in patients experiencing early virological failure under a triple combination including indinavir , 2001, AIDS.
[36] M. Hirsch,et al. Prevalence and predictive value of intermittent viremia with combination hiv therapy. , 2001, JAMA.
[37] R. Siliciano,et al. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. , 2001, JAMA.
[38] M. Kazatchkine,et al. Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. , 2001, The Journal of infectious diseases.
[39] R. Haubrich,et al. International perspectives on antiretroviral resistance. Clinical utility of resistance testing: retrospective and prospective data supporting use and current recommendations. , 2001, Journal of acquired immune deficiency syndromes.
[40] R. D’Aquila,et al. Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[41] R Hoh,et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. , 2001, The New England journal of medicine.
[42] A. Mocroft,et al. The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study , 2001, AIDS.
[43] P. Harrigan,et al. Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens , 2001, AIDS.
[44] E. De Clercq,et al. Prevalence of Genotypic Resistance among Antiretroviral Drug-Naive HIV-1-Infected Patients in Belgium , 2001, Antiviral therapy.
[45] E. Rosenberg,et al. Antiretroviral resistance during successful therapy of HIV type 1 infection. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[46] M. Kazatchkine,et al. Clinical Outcome of Patients with HIV-1 Infection according to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral Therapy , 2000, Annals of Internal Medicine.
[47] M. Mouroux,et al. Early Virological Failure in Naive Human Immunodeficiency Virus Patients Receiving Saquinavir (Soft Gel Capsule)-Stavudine-Zalcitabine (MIKADO Trial) Is Not Associated with Mutations Conferring Viral Resistance , 2000, Journal of Clinical Microbiology.
[48] Brendan A. Larder,et al. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples , 2000, AIDS.
[49] T. Merigan,et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy , 2000 .
[50] R. Harrigan,et al. Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies , 2000, AIDS.
[51] M. Hirsch,et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. , 2000, JAMA.
[52] V. Calvez,et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team). , 2000, JAMA.
[53] K. Hertogs,et al. HIV Drug Susceptibility and Treatment Response to Mega-Haart Regimen in Patients from the Frankfurt HIV Cohort , 2000, Antiviral therapy.
[54] S. Hammer,et al. The Relation between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy: Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis Plan , 2000, Antiviral therapy.
[55] P. Harrigan,et al. Suppression of plasma virus load below the detection limit of a human immunodeficiency virus kit is associated with longer virologic response than suppression below the limit of quantitation. , 1999, The Journal of infectious diseases.
[56] W. Miller,et al. Detectable HIV-1 RNA at levels below quantifiable limits by amplicor HIV-1 monitor is associated with virologic relapse on antiretroviral therapy. , 1999, AIDS.
[57] M. Zazzi,et al. Development and significance of the HIV-1 reverse transcriptase M184V mutation during combination therapy with lamivudine, zidovudine, and protease inhibitors. , 1999, Journal of acquired immune deficiency syndromes.
[58] J. Schapiro,et al. Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial , 1999, The Lancet.
[59] Richard A. Loftus,et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. , 1999, AIDS.
[60] A. Telenti,et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study , 1999, The Lancet.
[61] J. J. Henning,et al. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.
[62] J. Leonard,et al. The duration of viral suppression during protease inhibitor therapy for HIV‐1 infection is predicted by plasma HIV‐1 RNA at the nadir , 1998, AIDS.
[63] J. Mellors,et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor , 1996, Journal of virology.
[64] D. Kuritzkes,et al. Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic Millimeter , 1995 .
[65] Michael S Saag,et al. Treatment for Adult HIV Infection 2006 Recommendations of the International AIDS Society–USA Panel , 2006 .
[66] A. Hsu,et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. , 2004, The Journal of infectious diseases.